Practical Management of Bone Health and Bone Targeted Therapy in mCRPC VL

Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo

Details
In this conversation, Drs Alicia Morgans and Phillip Koo discuss optimizing the use of radium-223 through multidisciplinary collaboration. Dr. Koo highlights the transition from solely a diagnostic aspect of nuclear medicine practice, to now being more involved in therapies and patient-facing, There is a need to start developing the infrastructure to have more nuclear medicine clinics, where patie...

Multidisciplinary Team Approach to Treatment with Radium-223 for mCRPC - Brenda Martone

Details
Brenda Martone and Alicia Morgans discuss the multidisciplinary approach used at Northwestern University's Robert H Lurie Comprehensive Cancer Center to ensure the safe and efficient administration of Radium-223 to patients with metastatic castration-resistant prostate cancer (mCRPC). They discuss the importance of treating bone health in these patients and ensuring they are on a proper bone-stren...

Optimal Sequencing and Patient Selection for Radium-223, A Nuclear Medicine Perspective - Phillip Koo

Details
Dr Phillip Koo joins Alicia Morgans in offering a nuclear oncology physician perspective on working together with oncologists, urologists, nurse practitioners, and other members of the treating community on patient selection for treatment with radium. Dr. Koo highlights the importance of identifying patients who have bone predominant disease, with no visceral metastatic disease, and consider radiu...

Patient Selection for Treatment with Radium 223 - Tanya Dorff

Details
In this conversation, Alicia Morgans and Tanya Dorff discuss selecting the appropriate patient for treatment with Radium-223. Prostate cancer is so dominated by bone metastases which significantly impact a patient's day-to-day functioning and quality of life. The phase 3 ALSYMPCA trial showed that radium-223 dichloride (radium-223), improved overall survival compared with placebo and was well tole...

Supporting Patients Receiving Radium-223 for mCRPC - Fred Saad

Details
Fred Saad and Alicia Morgans discuss the management of patients who are receiving a bone supportive agent plus radium-223 in metastatic prostate cancer and the benefit in reduction of bone complications. Patients with prostate cancer who had bone fractures had a reduced survival rate. Doing everything clinicians can to reduce the risk of fractures can not only improve quality of life but may actua...

Combination Treatment Strategies with Radium-223 for mCRPC - Michael Morris

Details
Michael Morris joins Alicia Morgans in a discussion on combination therapies with Radium-223 for treating metastatic castration-resistant prostate cancer (mCRPC). Radium-223 is a bone-targeted alpha therapy and has been shown to prolong survival in patients with symptomatic mCRPC to the bone. Drs. Morris and Morgans highlight the DORA trial and focus on how combinations of treatment that either wo...

Treatment with Radium-223 and Effects on Bone Health in Patients with mCRPC - Fred Saad

Details
In this conversation, Fred Saad and Alicia Morgans discuss bone health in patients with metastatic castration-resistant prostate cancer (mCRPC) in the context of treatment with radium-223 and reducing skeletal complications with bone-directed therapy. Patients with mCRPC have been exposed to years of therapy that have made their bones more fragile and them at risk for fragility fractures. Drs. Mor...

Identifying the Right Patients For Treatment with Radium-223 for mCRPC - Brenda Martone

Details
Brenda Martone joins Alicia Morgans in a conversation on identifying appropriate patients for radium-223 (223Ra) treatment. Patients with metastatic disease to bone only, as well as patients who are symptomatic, bone paint, a loss of appetite, and worsening fatigue, are patients who can benefit from this treatment. In terms of treatment sequencing, radium-223 can be inserted anywhere along that co...

How Prior Exposure to Radiopharmaceuticals Effects The Treatment Paradigm Using Radium-223 for mCRPC - Michael Morris

Details
Michael Morris joins Alicia Morgans in a discussion on the sequencing of therapies in the context of radium for metastatic castration-resistant prostate cancer treatment. Their conversation focuses on thinking about prior exposure to radiopharmaceuticals when thinking about incorporating other radiopharmaceuticals into the treatment paradigm. As the conversation evolves, Drs. Morgans and Morris di...
email news signup